Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4296333 | 0.87 | TLR7 (0.34) | MEN1KMT2APOLBKDM4E | |
| SCHEMBL4298324 | 0.81 | KDM4E (0.35) | MEN1KMT2APOLBPABPC1KDM4E | |
| SCHEMBL4302608 | 0.78 | KDM4E (0.40) | MEN1KMT2APOLBPABPC1KDM4E | |
| SCHEMBL4299553 | 0.73 | PDE10A (0.38) | MEN1KMT2APOLBPABPC1KDM4E | |
| SCHEMBL192522 | 0.73 | TSHR (0.42) | MEN1KMT2APOLBPABPC1KDM4E | |
| SCHEMBL4757319 | 0.72 | LMNA (0.42) | MEN1KMT2APOLBKDM4EPDE10A | |
| SCHEMBL4758389 | 0.71 | TLR7 (0.45) | — | |
| SCHEMBL4299891 | 0.71 | KDM4E (0.44) | POLBKDM4E | |
| SCHEMBL4299889 | 0.71 | KDM4E (0.44) | POLBKDM4E | |
| SCHEMBL4302702 | 0.70 | KDM4E (0.39) | MEN1KMT2APOLBPABPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270443-A1 | 1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270443-A1 | 1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS | IL2, IL4I1, IFNG | MEN1 2721/4885KMT2A 3187/4885POLB 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.